Acacia Pharma Ltd   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Cambridge United Kingdom (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2009
NCT00895726
First Marketed Drug
2020
amisulpride
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ACACIA | Acacia Pharma Ltd | ACACIA PHARMA LTD

Active Ingredients

Marketed Drugs (2)

amisulpride (2020)

remimazolam (2020)

Drugs in Phase 3 Trials (5)

amisulpride (3 trials)

apd421 (9 trials)

dexamethasone (1 trial)

ondansetron (zofran) (3 trials)

remimazolam (1 trial)

Drugs in Phase 2 Trials (6)

apd405 (1 trial)

apd515 (1 trial)

aprepitant (Emend) (1 trial)

formoterol (foradil) (1 trial)

megestrol (megace) (1 trial)

urea (1 trial)

Drugs in Phase 1 Trials (1)

moxifloxacin (avelox) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cachexia (Phase 2)

Nausea (Phase 3)

Postoperative Nausea and Vomiting (Phase 3)

Vomiting (Phase 3)

Wasting Syndrome (Phase 2)

Xerostomia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 12